These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25054070)

  • 21. [Pharmaceutical Intervention According to Strict Management System Can Normalize Decreased Serum Calcium Level by Denosumab and Prevent Its Aggravation].
    Saito Y; Uchiyama K; Sakamoto T; Yamazaki K; Kubota K; Takekuma Y; Komatsu Y; Sugawara M
    Yakugaku Zasshi; 2021; 141(8):1023-1030. PubMed ID: 34334547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis.
    Yasuda Y; Iwama S; Arima H
    Endocr J; 2019 Mar; 66(3):271-275. PubMed ID: 30713246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection.
    Spångeus A; Rydetun J; Woisetschläger M
    Osteoporos Int; 2024 Jan; 35(1):173-180. PubMed ID: 37750930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures.
    Pittman K; Antill YC; Goldrick A; Goh J; de Boer RH
    Asia Pac J Clin Oncol; 2017 Aug; 13(4):266-276. PubMed ID: 27862983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
    Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
    Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
    Saito S; Sugo Y; Tsuburai T; Kurasawa K; Nakamura T; Yoshikata H; Miyagi E; Sakakibara H
    J Obstet Gynaecol Res; 2019 Apr; 45(4):908-914. PubMed ID: 30618176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe and refractory hypocalcaemia secondary to osteoblastic bone metastases in bladder signet ring carcinoma: A case report and literature review.
    Zeng W; Swee DS
    Medicine (Baltimore); 2022 Jul; 101(26):e29731. PubMed ID: 35776989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.
    Henry D; Vadhan-Raj S; Hirsh V; von Moos R; Hungria V; Costa L; Woll PJ; Scagliotti G; Smith G; Feng A; Jun S; Dansey R; Yeh H
    Support Care Cancer; 2014 Mar; 22(3):679-87. PubMed ID: 24162260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid progression of vascular and soft tissue calcification while being managed for severe and persistent hypocalcemia induced by denosumab treatment in a patient with multiple myeloma and chronic kidney disease.
    Ueki K; Yamada S; Tsuchimoto A; Tokumoto M; Kumano T; Kitazono T; Tsuruya K
    Intern Med; 2015; 54(20):2637-42. PubMed ID: 26466702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.
    Iizumi S; Shimoi T; Nishikawa T; Kitano A; Sasada S; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
    Intern Med; 2017 Nov; 56(21):2879-2882. PubMed ID: 28943574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
    Ishikawa K; Nagai T; Sakamoto K; Ohara K; Eguro T; Ito H; Toyoshima Y; Kokaze A; Toyone T; Inagaki K
    Ther Clin Risk Manag; 2016; 12():1831-1840. PubMed ID: 27980413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases.
    Lechner B; DeAngelis C; Jamal N; Emmenegger U; Pulenzas N; Giotis A; Sheehan P; Tsao M; Bedard G; Chow E
    Support Care Cancer; 2014 Jul; 22(7):1765-71. PubMed ID: 24515277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.
    Brown-Glaberman U; Stopeck AT
    Biologics; 2012; 6():89-99. PubMed ID: 22532777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe Hypocalcemia and Hypomagnesemia with Denosumab in Advanced Chronic Kidney Disease: Case Report and Literature Review.
    Marlow CF; Sharma S; Babar F; Lin J
    Case Rep Oncol Med; 2018; 2018():2059364. PubMed ID: 30405927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting.
    Huynh AL; Baker ST; Stewardson AJ; Johnson DF
    Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1274-1278. PubMed ID: 27255807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
    Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
    J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome.
    Shafqat H; Alquadan KF; Olszewski AJ
    Osteoporos Int; 2014 Mar; 25(3):1187-90. PubMed ID: 24158473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Side effects of bone-targeted therapies in advanced breast cancer.
    Domschke C; Schuetz F
    Breast Care (Basel); 2014 Oct; 9(5):332-6. PubMed ID: 25759613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Denosumab-Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease.
    Salim SA; Nair LR; Thomas L; Garla V; Palabindala V; Agarwal M; Fülöp T
    Am J Med Sci; 2018 May; 355(5):506-509. PubMed ID: 29753381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.